Wockhardt Intrinsic Value
WOCKPHARMA • Healthcare
Current Stock Price
₹1297.60
Primary Intrinsic Value
₹423.28
Market Cap
₹105.1K Cr
-60.0%
Downside
Median Value
₹519.04
Value Range
₹389 - ₹1150
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
WOCKPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹423.28 | ₹338.62 - ₹507.94 | -67.4% | EPS: ₹19.24, Sector P/E: 22x |
| Book Value Method | asset | ₹1149.88 | ₹1034.89 - ₹1264.87 | -11.4% | Book Value/Share: ₹574.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹793.09 | ₹713.78 - ₹872.40 | -38.9% | Revenue/Share: ₹396.54, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹982.72 | ₹884.45 - ₹1080.99 | -24.3% | EBITDA: ₹796.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹519.04 | ₹415.23 - ₹622.85 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹389.28 | ₹350.35 - ₹428.21 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹389.28 | ₹350.35 - ₹428.21 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹648.80 | ₹583.92 - ₹713.68 | -50.0% | ROE: 7.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹498.89 | ₹449.00 - ₹548.78 | -61.6% | EPS: ₹19.24, BVPS: ₹574.94 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
WOCKPHARMA Intrinsic Value Analysis
What is the intrinsic value of WOCKPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Wockhardt (WOCKPHARMA) is ₹519.04 (median value). With the current market price of ₹1297.60, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹389.28 to ₹1149.88, indicating ₹389.28 - ₹1149.88.
Is WOCKPHARMA undervalued or overvalued?
Based on our multi-method analysis, Wockhardt (WOCKPHARMA) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.72 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 7.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.39x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Wockhardt
Additional stock information and data for WOCKPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-22 Cr | ₹-412 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹219 Cr | ₹150 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹153 Cr | ₹94 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹413 Cr | ₹311 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-287 Cr | ₹-287 Cr | Negative Cash Flow | 3/10 |